Percutaneous adenoviral gene transfer into porcine coronary arteries

Is catheter-based gene delivery adapted to coronary circulation?

Olivier Varenne, Robert D. Gerard, Peter Sinnaeve, Hilde Gillijns, Desire Collen, Stefan Janssens

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Recombinant adenoviral (Ad) vectors represent an efficient gene transfer system for targeting the cardiovascular system. Phenotypic modulation of coronary vascular cells in vivo is, however, critically dependent on the efficacy of local delivery devices. Four local drug delivery catheters were tested for intracoronary gene transfer efficiency: the Infiltrator (INF, n = 10), the Crescendo (CRE, n = 10), the Infusasleeve (SLE, n = 8), and the Remedy balloon (channel balloon [CHA], n = 8). After balloon injury of the LAD, Ad vector containing the firefly luciferase cDNA (AdCMVluc, 1.5 x 1010 plaque-forming units) was administered at the site of injury. On day 4, tissue samples from different regions in the heart and from the liver were assayed for luciferase activity to evaluate local and systemic gene transfer. INF, CRE, and SLE catheters showed higher transduction levels of the target LAD segment than did the CHA catheter (median luciferase activity = 4.2 x 106, 11 x 106, and 1.3 x 106 light units [LU]/vessel versus 0.09 x 106 LU/vessel, respectively, p < 0.05). Luciferase activity was occasionally observed in nontarget tissues (right and left ventricular free wall, distal LAD, and liver) and was not significantly different between groups. The viral circulatory half-life was similar for the four groups (< 1 min). Gene transfer efficiency was positively correlated with the degree of injury for the intralumenal catheters (CRE, SLE, and CHA) but was independent of the vessel wall injury for the intramural INF. Local drug delivery catheters enable efficient vascular gene transfer in balloon-injured coronary arteries, a prerequisite for further development of intracoronary gene therapy for restenosis.

Original languageEnglish (US)
Pages (from-to)1105-1115
Number of pages11
JournalHuman Gene Therapy
Volume10
Issue number7
DOIs
StatePublished - May 1 1999

Fingerprint

Coronary Circulation
Coronary Vessels
Swine
Catheters
Luciferases
Genes
Wounds and Injuries
Blood Vessels
Firefly Luciferases
Light
Liver
Cardiovascular System
Pharmaceutical Preparations
Genetic Therapy
Half-Life
Complementary DNA
Equipment and Supplies

ASJC Scopus subject areas

  • Genetics

Cite this

Percutaneous adenoviral gene transfer into porcine coronary arteries : Is catheter-based gene delivery adapted to coronary circulation? / Varenne, Olivier; Gerard, Robert D.; Sinnaeve, Peter; Gillijns, Hilde; Collen, Desire; Janssens, Stefan.

In: Human Gene Therapy, Vol. 10, No. 7, 01.05.1999, p. 1105-1115.

Research output: Contribution to journalArticle

Varenne, Olivier ; Gerard, Robert D. ; Sinnaeve, Peter ; Gillijns, Hilde ; Collen, Desire ; Janssens, Stefan. / Percutaneous adenoviral gene transfer into porcine coronary arteries : Is catheter-based gene delivery adapted to coronary circulation?. In: Human Gene Therapy. 1999 ; Vol. 10, No. 7. pp. 1105-1115.
@article{f9379964a12043daaf1f1eecaef02677,
title = "Percutaneous adenoviral gene transfer into porcine coronary arteries: Is catheter-based gene delivery adapted to coronary circulation?",
abstract = "Recombinant adenoviral (Ad) vectors represent an efficient gene transfer system for targeting the cardiovascular system. Phenotypic modulation of coronary vascular cells in vivo is, however, critically dependent on the efficacy of local delivery devices. Four local drug delivery catheters were tested for intracoronary gene transfer efficiency: the Infiltrator (INF, n = 10), the Crescendo (CRE, n = 10), the Infusasleeve (SLE, n = 8), and the Remedy balloon (channel balloon [CHA], n = 8). After balloon injury of the LAD, Ad vector containing the firefly luciferase cDNA (AdCMVluc, 1.5 x 1010 plaque-forming units) was administered at the site of injury. On day 4, tissue samples from different regions in the heart and from the liver were assayed for luciferase activity to evaluate local and systemic gene transfer. INF, CRE, and SLE catheters showed higher transduction levels of the target LAD segment than did the CHA catheter (median luciferase activity = 4.2 x 106, 11 x 106, and 1.3 x 106 light units [LU]/vessel versus 0.09 x 106 LU/vessel, respectively, p < 0.05). Luciferase activity was occasionally observed in nontarget tissues (right and left ventricular free wall, distal LAD, and liver) and was not significantly different between groups. The viral circulatory half-life was similar for the four groups (< 1 min). Gene transfer efficiency was positively correlated with the degree of injury for the intralumenal catheters (CRE, SLE, and CHA) but was independent of the vessel wall injury for the intramural INF. Local drug delivery catheters enable efficient vascular gene transfer in balloon-injured coronary arteries, a prerequisite for further development of intracoronary gene therapy for restenosis.",
author = "Olivier Varenne and Gerard, {Robert D.} and Peter Sinnaeve and Hilde Gillijns and Desire Collen and Stefan Janssens",
year = "1999",
month = "5",
day = "1",
doi = "10.1089/10430349950018102",
language = "English (US)",
volume = "10",
pages = "1105--1115",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "7",

}

TY - JOUR

T1 - Percutaneous adenoviral gene transfer into porcine coronary arteries

T2 - Is catheter-based gene delivery adapted to coronary circulation?

AU - Varenne, Olivier

AU - Gerard, Robert D.

AU - Sinnaeve, Peter

AU - Gillijns, Hilde

AU - Collen, Desire

AU - Janssens, Stefan

PY - 1999/5/1

Y1 - 1999/5/1

N2 - Recombinant adenoviral (Ad) vectors represent an efficient gene transfer system for targeting the cardiovascular system. Phenotypic modulation of coronary vascular cells in vivo is, however, critically dependent on the efficacy of local delivery devices. Four local drug delivery catheters were tested for intracoronary gene transfer efficiency: the Infiltrator (INF, n = 10), the Crescendo (CRE, n = 10), the Infusasleeve (SLE, n = 8), and the Remedy balloon (channel balloon [CHA], n = 8). After balloon injury of the LAD, Ad vector containing the firefly luciferase cDNA (AdCMVluc, 1.5 x 1010 plaque-forming units) was administered at the site of injury. On day 4, tissue samples from different regions in the heart and from the liver were assayed for luciferase activity to evaluate local and systemic gene transfer. INF, CRE, and SLE catheters showed higher transduction levels of the target LAD segment than did the CHA catheter (median luciferase activity = 4.2 x 106, 11 x 106, and 1.3 x 106 light units [LU]/vessel versus 0.09 x 106 LU/vessel, respectively, p < 0.05). Luciferase activity was occasionally observed in nontarget tissues (right and left ventricular free wall, distal LAD, and liver) and was not significantly different between groups. The viral circulatory half-life was similar for the four groups (< 1 min). Gene transfer efficiency was positively correlated with the degree of injury for the intralumenal catheters (CRE, SLE, and CHA) but was independent of the vessel wall injury for the intramural INF. Local drug delivery catheters enable efficient vascular gene transfer in balloon-injured coronary arteries, a prerequisite for further development of intracoronary gene therapy for restenosis.

AB - Recombinant adenoviral (Ad) vectors represent an efficient gene transfer system for targeting the cardiovascular system. Phenotypic modulation of coronary vascular cells in vivo is, however, critically dependent on the efficacy of local delivery devices. Four local drug delivery catheters were tested for intracoronary gene transfer efficiency: the Infiltrator (INF, n = 10), the Crescendo (CRE, n = 10), the Infusasleeve (SLE, n = 8), and the Remedy balloon (channel balloon [CHA], n = 8). After balloon injury of the LAD, Ad vector containing the firefly luciferase cDNA (AdCMVluc, 1.5 x 1010 plaque-forming units) was administered at the site of injury. On day 4, tissue samples from different regions in the heart and from the liver were assayed for luciferase activity to evaluate local and systemic gene transfer. INF, CRE, and SLE catheters showed higher transduction levels of the target LAD segment than did the CHA catheter (median luciferase activity = 4.2 x 106, 11 x 106, and 1.3 x 106 light units [LU]/vessel versus 0.09 x 106 LU/vessel, respectively, p < 0.05). Luciferase activity was occasionally observed in nontarget tissues (right and left ventricular free wall, distal LAD, and liver) and was not significantly different between groups. The viral circulatory half-life was similar for the four groups (< 1 min). Gene transfer efficiency was positively correlated with the degree of injury for the intralumenal catheters (CRE, SLE, and CHA) but was independent of the vessel wall injury for the intramural INF. Local drug delivery catheters enable efficient vascular gene transfer in balloon-injured coronary arteries, a prerequisite for further development of intracoronary gene therapy for restenosis.

UR - http://www.scopus.com/inward/record.url?scp=0033135213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033135213&partnerID=8YFLogxK

U2 - 10.1089/10430349950018102

DO - 10.1089/10430349950018102

M3 - Article

VL - 10

SP - 1105

EP - 1115

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 7

ER -